Changing the Channel on Stroke Treatment: Novel Technology Provides New Path to Prevent Neuronal Death

Lixia Yue’s team discovered that a specific peptide sequence can disrupt the interaction between an ion channel and receptors in our brain responsible for neuronal death during an ischemic stroke

Lixia Yue's team has developed a peptide that can prevent neuronal death following a stroke. They are now looking to commercialize this innovation.

Stroke is a leading cause of disability and death in the U.S., with roughly 800,000 Americans suffering a stroke every year.

There are two kinds of stroke: ischemic and hemorrhagic. Ischemic stroke occurs when a blood clot forms and blocks blood supply to the brain. This cuts off the blood’s oxygen and nutrient supply. Hemorrhagic stroke occurs when a blood vessel bursts and leaks out into the brain.

Despite the widespread impact of stroke, there is still a lack of effective treatment. Lixia Yue, associate professor of cell biology at UConn School of Medicine, has made a discovery that could change this.

In our brains, we have receptors known as NMDA receptors. They play a role in memory and a host of physiological functions. However, these receptors also play a key role in the death of brain cells (neurons) during a stroke, causing long-term damage or death. When activated during a stroke, these receptors allow an overabundance of calcium ions to pass through and flood cells and damage or kill them.

Given its critical role in neuronal death during stroke, NMDA receptors have been a target for stroke treatments for 50 years without much success. These efforts have stalled because blocking this receptor has severe side effects.

“This receptor has a lot of physiological functions,” Yue says. “So, when it’s blocked, our physiological functioning will be impacted.”

Yue’s breakthrough discovery was that stroke damage occurs specifically when an ion channel called TRPM2 interacts with NMDA receptors under conditions of oxidative stress present during a stroke. She identified a short (16 amino acid long) sequence on TRPM2 that is responsible for the interaction that leads to neuronal death.

Critically, TRPM2 and NMDA receptors do not interact under normal conditions, meaning Yue’s approach avoids the risks associated with earlier attempts to outright block NMDA receptors.

“The target we identified is very unique,” Yue says. “The mechanism is very specific.”

Yue produced a peptide that mimics the TRPM2 sequence that binds to NMDA receptor and therefore disrupts the interaction between TRPM2 and NMDA receptors. This disrupting peptide can be administered immediately following a stroke. The goal of this approach is to reduce the number of neurons that die by disrupting the interaction between TRPM2 and NMDA receptors.

Yue’s work focused on ischemic stroke, which account for 85% of all strokes.

To test its efficacy, Pengyu Zong, a graduate student in Yue’s group, and the first author of the paper, conducted an in-vivo trial using mice, the findings of which were recently published in Neuron.

After inducing a stroke, Yue and her team injected the mice with a peptide two hours after the stroke. This time lag was designed to mimic the delay someone may have between a stroke and when they make it to a hospital and to allow enough neurons to die for them to make useful comparisons.

They continued the injections every 12 hours for seven days. This approach safely covers the potential impact of delayed neuronal death which tends to occur around three days following a stroke.

Yue’s peptide effectively blocked the interaction between NMDA receptors and TRPM2 after a stroke in the mouse models. Yue and her team saw greatly reduced brain injury from 37% to only 18-19% with the peptide injection.

The next steps for this technology will be to determine what the ideal dosage and timing between doses is. Yue says they will also look to evaluate how long after a stroke this treatment may be effective.

“When patients get to the hospital, sometimes it’s not that fast,” Yue says. “So, I think that’s a very important clinical question.”

Yue says in the future she may look to develop a small molecule to mimic the effect of the disrupting peptide since small molecules have an easier time working their way into the body than peptides and may be easier to produce and administer.


UConn Technology Commercialization Services has filed patent protection for this technology. TCS is looking for collaborators/licensees in the industry to move this technology forward. For further information, please contact Amit Kumar at

Yue holds a Ph.D. from McGill University. She completed postdoctoral training at Howard Hughes Medical Institute, Children’s Hospital, Harvard Medical School. Her research focuses on calcium signaling mechanisms and their potential roles under physiological and pathological conditions and the function of TRP channels.

Follow UConn Research on Twitter & LinkedIn.